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Abstract 
Background: Human immunodeficiency virus (HIV) compromises the nutritional status of infected individuals and in 
turn, malnutrition worsens the effects of the infection itself by weakening the immune system consequently acceler-
ating disease progression and death. However, few studies have examined the association between nutritional status 
at antiretroviral therapy (ART) initiation and early mortality. Therefore, this study assesses pre-ART nutritional status 
and other baseline characteristics and mortality among adult patients on ART at Fiche Hospital, Ethiopia.
Methods: A retrospective cohort study was conducted among 489 ART enrolled adult patients between August 01, 
2006 and September 30, 2013 in Fiche Hospital. Study participants were selected by using systematic random sam-
pling method. Actuarial table was used to estimate survival of patients after ART initiation and log rank test was used 
to compare the survival curves. Cox proportional-hazard regression was used to determine independent predictors of 
time to death.
Results: Most of the study subjects were females 254 (51.9%). A total of 489 patients were included in the analysis, 
of whom 87 died during a median study follow-up of 22 months. The estimated mortality among malnourished was 
21, 28, 33, and 38% at 5, 10, 15, and 25 months respectively with mortality incidence density of 5.63 deaths per 100 
person years. The independent predictors of mortality were: BMI <18.5 kg/m2 (AHR = 5.4 95% CI 3.03–9.58), base-
line ambulatory functional status (AHR = 3.84; 95% CI 2.19–6.74), bedridden functional status (AHR = 4.78; 95% CI 
2.14–10.65), WHO clinical stage III (AHR 2.21; 95% CI 1.16–4.21), WHO clinical stage IV (AHR 4.05; 95% CI 1.50–10.97) 
and CD4 count less than 200 cells/μl (AHR = 2.95; 95% CI 1.48–5.88), two and more opportunistic infections (AHR 
2.30; 95% CI 1.11–4.75).
Conclusions: Undernutrition at the time of ART initiation was associated with increased risk of death, particularly 
during the first 3 months after ART initiation. Interventions to promote earlier HIV diagnosis and treatment and 
integrating nutrition counseling at all stages of ART implementation may improve ART outcomes in this vulnerable 
population.
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Background
Provision of antiretroviral therapy (ART) for HIV-infected 
individuals is rapidly expanding in sub-Saharan Africa [1]. 
HIV itself increases resting energy expenditure indepen-
dently of viral load, further contributing to HIV-associated 
weight loss. As HIV infection progresses, it can cause a cat-
abolic state that is compounded by a lack of caloric intake, 
increasing the severity of preexisting undernutrition [2].
Body mass index (BMI) at ART initiation was defined 
as BMI below 18.5 kg/m2 indicates that a person is under-
weight, 18.5–24.9  kg/m2 is normal weight, and 25.0–
29.9 kg/m2 is overweight and 30.0 kg/m2 or above is obese. 
HIV compromises the nutritional status of infected indi-
viduals and in turn, malnutrition worsens the effects of the 
infection itself by weakening the immune system conse-
quently accelerating disease progression and death [3].
An improved understanding of the role of nutri-
tional status in HIV disease progression may help in 
the development of strategies to reduce mortality after 
ART initiation. To the best of our knowledge, no pre-
vious study has examined the effect of pre-ART nutri-
tional status on time to death in the cohort of ART 
clients enrolled during the specified time in the study 
area. This study, therefore, intends to examine the asso-
ciations between nutritional status and its associated 
mortality among adult patients on ART. Moreover, this 
study results serve as baseline data for further investi-
gations and provides input for health planners and pol-
icy makers.
Methods
Institution based retrospective cohort study was conducted 
in Fiche Hospital from Jan 01–31/2014. Fiche town has one 
zonal hospital and two health centers for the catchment area 
population, which provide ART service for 3937 patients 
enrolled. Peoples’ living with HIV/AIDS (PLWHA).
Inclusion criteria
HIV positive adults aged 18  years or older who started 
ART with complete intake form, registers that have been 
in follow-up from 2006 to 2013.
Exclusion criteria
  • Diagnosis is made outside of health institution 
(transfer in).
  • Loss to follow up, transfer out.
  • Pregnant and lactating women at the time of ART 
initiation.
Sample size determination
Sample size was determined using a formula for two pop-
ulation proportions based on the assumption that type 
I error 5%, power of 90% on exposure (malnourished on 
pre-ART treatment) and non-exposure (non-malnourished 
on pre-ART treatment) was taken from previous study [15].
 α = level of significance, power = 1 − β = 90%, Zβ = 1.282.
The sample size was 163 for n1 (exposed group) and 
326 for n2 (non-exposed group). Using proportional allo-
cation to the malnourished and non-malnourished adult 
patients, a total of 489 samples taken.
Sampling technique
A cohort of antiretroviral patients who were initiated 
treatment between August 2006 and September 2013 
were included in the study and their profiles were evalu-
ated. After thorough evaluation, the number of HIV cli-
ents from the list that fulfills the inclusion criteria were 
1228. A total of 489 Study participants were selected by 
using systematic random sampling method by which one 
random number in the Patient’s ART unique identifica-
tion numbers as a starting point. The first HIV client 
was selected by lottery method among the first sampling 
intervals from the evaluated profiles (Fig. 1).
Data collection methods and instruments
A data collection tool was developed from ART entry and 
follow-up form being used in the ART clinic. The follow-
up documents was evaluated thoroughly about its com-
pleteness before data collection takes place. The data was 
collected by reviewing medical record registers, laboratory 
requests, and follow-up form of ART. The data was col-
lected from Jan 01–31/2014. Data quality was controlled 
through continuous supervision and random check-up of 
the data collection. Three days training was given for data 
collectors and supervisors. Data quality control during 
data entry was done by double entry to EPI-info Version 
3.5.3 computer software and through multivariate analysis.
Ethical approval was obtained from the Institutional 
Health Research Ethics Review Committee (IHRERC) of 
Harar campus, Haramaya University, College of Medi-
cine and Health Sciences. Following the approval by 
IHRERC, official letter of ethical clearance was written 
to the concerned bodies by the School of Public Health. 
As the study was conducted through review of medical 
records, the individual patients were not subjected to any 
harm and personal identifiers were not used on data col-
lection forms and confidentiality was maintained.
Data processing and analysis
The data were entered into Epi-Info Version 3.5.3 and 
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12 statistical packages for data processing and analy-
sis. Actuarial life table analysis was used to estimate 
cumulative proportion of surviving after initiation of 
ART. Kaplan–Meier Survival function was used to esti-
mate mortality of HIV patients on ART. The log-rank 
test was conducted to compare time to death between/
among various levels. Before running the Cox regres-
sion model, assumption of proportional-hazard was 
checked by Schoenfeld test and the assumption was not 
violated. Cox proportional-hazard regression was used 
to calculate the bivariate and adjusted hazard rate to 




The study involved a total of 489 adults of people living 
with HIV/AIDS (PLWHA) on ART; 163 (33.3%) were 
malnourished (BMI < 18.5 kg/m2) and 326 (66.7%) were 
non-malnourished adults (BMI  ≥  18.5  kg/m2). Most of 
the study subjects were females 254 (51.9%) and males 
235 (48.1%). The overall mean(±SD) age at ART initia-
tion was 34.36 ± 9.24 years, out of which most of them 
201 (41.1%) were in the age range of 18–29 years followed 
by 149 (30.5%) of 30–39 years (Table 1).
Baseline clinical and laboratory information of the cohort
The baseline mean (±SD) values for BMI of the partici-
pants was 19.75 ± 2.96. The median weight at ART initia-
tion was 51 kg [interquartile range (IQR 45–57 kg)]. The 
median CD4 cell count at ART initiation was 145 cells/
μl (IQR 80–222). Three hundred thirty five (68.5%) of 
the patients had CD4 counts <200 cells/μl. The median 
hemoglobin level was 12.90  g/dl (IQR 10.9–14.6). Most 
of the study subjects at ART initiation were 220 (45%) in 
WHO stage III and 197 (40.3%) in WHO stage II. With 
regard to functional status, 197 (40.3%) participants were 
ambulatory at baseline and 27 (5.5%) were bedridden. 
Out of those who participated, 304 (62.2%) had no pre-
vious opportunistic infection, 68 (13.9%) had one previ-
ous opportunistic infection and 117 (23.9%) had two and 
more previous opportunistic infections (Table 2).
Baseline demographic and clinical characteristics 
and associated mortality of patients on ART
From the study subjects, the proportion of mortality is 
higher among the age group of 50+  years followed by 
40–49  years (20.5 vs. 19%). With regard to educational 
status, 36 (26.1%) of the participants who had no educa-
tion died after initiation of ART. The proportion of mor-
tality is higher among males than females (19 vs. 17%) 
(Table 3).
Survival analysis
A total of 489 HIV infected individuals were enrolled in 
a retrospective study for a median (IQR) of 22 (14–34) 
months; 17 (5–34) months among malnourished adults 
and 23 (17–34) months among non-malnourished adult 
patients. All the study subjects contributed 1545.4 person 
year of observation (PYO); 429.35 PYO for those who were 
From August 2006 to September 2013 (n=3346) 
Not eligible (2118) Eligible (1228)
< 18 years (241)  
Transfer in (230) 
Transfer out (959) 
Lost to follow-up (51)
Incomplete data (48) 






N= 489 selected using SRS 
 n=163  n=326
Fig. 1 Profile of PLWHA enrolled on ART in Fiche Hospital, North Shoa, Ethiopia
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Table 1 Socio-demographic characteristics of HIV-positive patients at ART initiation in Fiche Hospital, North Shoa, 2006–
2013, (N = 489)
P value <0.05 = statistically significant difference
Characteristics Malnourished (n = 163) Non malnourished (n = 326) Total (N = 489) P value
Number (%) Number (%) Number (%)
Sex
 Male 95 (58.3) 140 (42.9) 235 (48.1) 0.002
 Female 68 (41.7) 186 (57.1) 254 (51.9)
Age groups (years)
 18–29 68 (41.7) 133 (40.8) 201 (41.1) 0.786
 30–39 53 (32.5) 96 (29.4) 149 (30.5)
 40–49 31 (19.0) 69 (21.2) 100 (20.4)
 50+ 11 (6.7) 28 (8.6) 39 (8.0)
Marital status
 Single 24 (14.7) 37 (11.3) 61 (12.5) 0.139
 Married 71 (43.6) 179 (54.9) 250 (51.1)
 Separated 21 (12.9) 43 (13.2) 64 (13.1)
 Divorced 22 (13.5) 31 (9.5) 53 (10.8)
 Widowed 25 (15.3) 36 (11.0) 61 (12.5)
Educational status
 No education 60 (36.8) 78 (23.9) 138 (28.2) 0.004
 Primary 57 (35.0) 107 (32.8) 164 (33.5)
 Secondary 36 (22.1) 116 (35.6) 152 (31.1)
 Tertiary 10 (6.1) 25 (7.7) 35 (7.2)
Table 2 Baseline clinical characteristics of HIV patients in Fiche Hospital (N = 489)
Characteristics Malnourished (n = 163) Non malnourished (n = 326) Total (N = 489) P value
Number (%) Number (%) Number (%)
Functional status
 Working 49 (30.1) 216 (54.2) 265 (54.2) 0.0001
 Ambulatory 94 (57.7) 103 (31.6) 197 (40.3)
 Bedridden 20 (12.3) 7 (2.1) 27 (5.5)
WHO clinical stage
 Stage I 7 (4.3) 41 (12.6) 48 (9.8) 0.0001
 Stage II 58 (35.6) 139 (42.6) 197 (40.3)
 Stage III 84 (51.5) 136 (41.7) 220 (45)
 Stage IV 14 (8.6) 10 (3.1) 24 (4.9)
TB history
 Yes 75 (46) 73 (22.4) 148 (30.3) 0.0001
 No 88 (54) 253 (77.6) 341 (69.7)
Hemoglobin count (g/dl)
 <10 34 (21.5) 30 (9.7) 64 (13.7) 0.0001
 ≥10 124 (78.5) 279 (90.3) 403 (86.3)
Previous OIs
 None 86 (52.8) 218 (66.9) 304 (62.2) 0.0001
 One 18 (11.0) 50 (15.3) 68 (13.9)
 2+ 59 (36.2) 58 (17.8) 117 (23.9)
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malnourished HIV adult patients and 1116.05 PYO for 
non-malnourished patients. Out of the study subjects, 87 
patients died during the study period giving a mortality rate 
of 5.63 per 100 person-year observations (87 deaths/1545.4 
PYO). Of the 87 deaths, 27 (31%) occurred within the first 
3 months of ART initiation and 41 (47.1%) died in the first 
year of follow-up. The overall estimated survival duration 
after ART initiation was 48 (95% CI 46.32–50.84) months.
Actuarial life table analysis showed that probability of 
survival time among malnourished adult ART patients 
was 79, 91, 93, 94, and 98% at 5, 10, 15, 20, and 30 months 
respectively. The probability of survival time among non-
malnourished adults was 97, 99, 99 and 98% at 5, 10, 15 
and 35 months respectively (Fig. 2).  
Survival time of adult HIV‑positive patients at ART 
initiation
Kaplan–Meier analysis of patients at ART 
by socio‑demographic characteristics
The overall estimated survival time after ART initiation 
using Kaplan–Meier survival analysis was 48  months 
(95% CI 45.32–50.68). The survival experience after ini-
tiation of ART estimated by the Kaplan–Meier survival 
analysis by educational status showed that there was sig-
nificant difference in median survival time among the 
groups, no education 44  months (95% CI 40.18–48.82) 
and secondary education 53  months (95% CI 49.98–
56.02), (log rank test X2 = 14.321, P = 0.002).
Kaplan–Meier analysis of patients at ART by baseline clinical 
characteristics
There was significant difference in median survival time 
among working functional status 54  months (95% CI 
52.49–57.51), ambulatory status 41  months (95% CI 
36.88–44.22) and bedridden 34  months (95% CI 24.86–
43.14) (log rank test X2 = 51.976, P = 0.0001).
Predictors of mortality
After adjustment, the following characteristics at the 
initiation of the ART were the independent significant 
predictors of mortality: BMI < 18.5 kg/m2, baseline func-
tional status (Ambulatory and Bedridden), WHO stage 
III and IV, CD4 cell count <200 cells/µl and opportun-
istic infections with two and more. Patients with a BMI 
<18  kg/m2 had a 5.4-fold increased risk of mortality 
(95% CI 3.03–9.58) as compared to those with ≥18.5 kg/
m2. The hazard rate for dying is 3.84 times more with 
baseline functional status of ambulatory compared to 
patients with functional status of working (AHR = 3.84; 
95% CI 2.19–6.74). Similarly, Patients with baseline 
functional status of bedridden had 4.78 times increased 
risk of death as compared to patients with baseline 
functional status of working (AHR = 4.78; 95% CI 2.14, 
10.65). HIV-infected patients with baseline WHO clini-
cal stage III had twofold increased risk of death com-
pared to patients with stage I and II (AHR 2.21; 95% CI 
Table 3 Baseline demographic and  clinical characteristics 




Total Alive n = 402 Death n = 87 P value
Number (%) Number (%) Number (%)
Sex
 Male 221 (45.2) 179 (81) 42 (19) 0.604
 Female 268 (54.8) 223 (83) 45 (17)
Age groups (years)
 18–29 201 (41.1) 167 (83.1) 34 (16.9) 0.937
 30–39 149 (30.5) 123 (82.5) 26 (17.5)
 40–49 100 (20.4) 81 (81) 19 (19)
 50+ 39 (8.0) 31 (79.5) 8 (20.5)
Nutritional status
 Malnourished 163 (33.3) 122 (74.8) 41 (25.2) 0.004
 Non-mal-
nourished
326 (66.7) 280 (85.9) 46 (14.1)
Educational status
 No education 138 (28.2) 102 (73.9) 36 (26.1) 0.011
 Primary 164 (33.5) 138 (84.1) 26 (15.9)
 Secondary 152 (31.1) 129 (84.9) 23 (15.1)
 Tertiary 35 (7.2) 33 (94.3) 2 (5.7)
Functional status
 Working 265 (54.2) 257 (96.9) 8 (3.1) 0.0001
 Ambulatory 197 (40.3) 128 (64.9) 69 (35.1)
 Bedridden 27 (5.5) 17 (62.9) 10 (37.1)
WHO clinical stage
 Stage I 48 (9.8) 47 (97.9) 1 (2.1) 0.0001
 Stage II 197 (40.3) 192 (97.5) 5 (2.5)
 Stage III 220 (45) 149 (67.7) 71 (32.3)
 Stage IV 24 (4.9) 14 (58.3) 10 (41.7)
Previous OIs
 None 304 (62.2) 289 (95.1) 15 (4.9) 0.0001
 One 68 (13.9) 50 (73.5) 18 (26.5)




83 (17) 72 (86.7) 11 (13.3) 0.245
 d4t(30)-3TC-
EFV
64 (13.1) 51 (79.6) 13 (20.4)
 AZT-3TC-NVP 230 (47) 193 (83.9) 37 (16.1)
 AZT-3TC-EFV 112 (22.9) 86 (76.8) 26 (23.2)
HIV related counseling
 Yes 141 (28.8) 135 (95.7) 6 (4.3) 0.0001
 No 348 (71.2) 267 (76.7) 81 (23.7)
TB history
 Yes 148 (30.3) 101 (68.2) 47 (31.8) 0.0001
 No 341 (69.7) 301 (88.2) 40 (11.8)
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(WHO clinical stage III) at the time of treatment initiation 
and might be due to delayed diagnosis and/or treatment.
This study revealed that a low baseline body mass index 
(BMI) at the start of ART was an independent predic-
tor of early mortality (i.e., in the first 90 days of therapy). 
This is in line with studies conducted in several sub-
Saharan Africa [5, 11, 13–16]. This might be as a result 
of the aggregate effects of malnutrition-induced immune 
system dysfunction, a higher burden of opportunistic 
infections, metabolic derangement and anthropomet-
ric variations. Even after the initiation of ART, the side 
effects of certain antiretroviral drugs (e.g., nausea, insom-
nia) may prevent adequate intake [17], and malnutrition 
and low body weight may potentiate drug toxicity [18].
Patients with advanced clinical diseases (WHO stage 
III or IV) had higher mortality compared to patients with 
WHO stage I or II. This finding was supported by several 
other studies [11, 12, 19–22]. This might be due to the 
fact that patients died mostly because of their late initia-
tion of ART when they had the worst health conditions. 
In contrast, a study conducted in Western Ethiopia and 
South Western Uganda reported that WHO clinical stage 
was not found to be associated with mortality [7, 23].
In this study, patients with two and above opportunis-
tic infections had 2.3 times higher mortality as compared 
to those who had no starting opportunistic infection. 
Fig. 2 Survival graph of HIV patients at ART initiation by nutritional status in Fiche Hospital, Ethiopia
1.16–4.21), and the risk of death among WHO clinical 
stage IV patients was even higher- compared to stage I 
or II patients (AHR 4.05; 95% CI 1.50, 10.97). Patients 
starting ART with CD4 count less than 200 cells/μl 
had threefold higher death hazard (95% CI 1.48–5.88) 
as compared to those starting ART with more than 
200 cells/μl. Patients with two and above opportunistic 
infections had 2.3 times higher mortality as compared to 
those who had no starting opportunistic infection (AHR 
2.30; 95% CI 1.11, 4.75) (Table 4).
Discussion
Mortality in this study was found to be 5.63/100 person 
years at risk with most of the deaths occurred during the 
first 3  months following ART initiation. This result is in 
agreement with the study done in Burkina Faso [4]. How-
ever, this finding was low compared to common rates in 
resources-limited countries [5] and higher compared 
to 2.03/100 persons-years in the Eastern Ethiopia and 
1.89/100 persons-years in Western Ethiopia respectively 
[6, 7]. The high early mortality observed in our study is 
in line with other similar studies from resource-limited 
settings, including Ethiopia [5, 8–12]. This may partly be 
explained by the fact that the majority of patients that 
68.5% patients had advanced disease (CD4 count ≤200 
cells/μl) and 45% patients had advanced clinical symptoms 
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This study established a similar finding with the studies 
in sub-Saharan Africa that showed OIs were found to 
be significant predictors of death among patients under 
ART [11, 13, 24, 25].
Adult HIV-infected patients who were bedridden at 
ART initiation had higher risk of mortality compared to 
the patients with working functional status at treatment 
initiation. This result is in line with the study done in East-
ern Ethiopia and those described elsewhere [6, 21, 23, 26].
Patients starting ART treatment with CD4 cell count 
≤200 cells/μl was an independent predictor of mor-
tality in this study. This finding is consistent with stud-
ies [4, 6, 12, 20, 25, 27]. Studies have substantiated 
the fact that low CD4 cell count, a marker of advanced 
immunodeficiency, was associated with opportunistic 
infection thereby increasing the likelihood of death [28]. 
This may partly be explained by the fact that the majority 
of patients (75.5%) had a CD4 ≤200 cells/μl, which could 
have made the comparison with higher CD4 counts sta-
tistically unstable.
Our study was subjected to several important limi-
tations. Selection bias is possibly introduced due to 
the fact that patients with incomplete records of vari-
ables were excluded. In addition, because we could not 
ascertain outcomes of patients lost to follow-up, our 
mortality results might be an underestimation. Anthro-
pometric measurements might not be measured or 
recorded correctly.
Table 4 Bivariate and  multivariate Cox-regression analysis of  socio-demographic and  baseline clinical characteristics 
of the cohort studied in Fiche Hospital, North Shoa during September 2006 to 2013, (N = 489 patients)
1.00 = Reference * P value <0.05, ** P value ≤0.001
Covariates Number at risk Number of deaths Crude HR (95% CI) Adjusted HR (95% CI)
Educational status
 No education 138 36 1.86 (0.73, 4.76) 1.35 (0.50, 3.6)
 Primary 164 26 1.60 (0.63, 4.10) 2.05 (0.78, 5.36)
 Secondary 152 23 0.61 (0.22, 1.71) 0.92 (0.31, 2.74)
 Tertiary 35 2 1
Nutritional status
 Malnourished 163 41 7.58 (4.63, 12.39) 5.40 (3.03, 9.58)**
 Non-malnourished 326 46 1
Functional status
 Working 265 8 1
 Ambulatory 197 69 4.91 (2.91, 8.26) 3.84 (2.19, 6.74)**
 Bedridden 27 10 6.86 (3.26, 14.44) 4.78 (2.14, 10.65)**
WHO clinical stage
 Stage I and II 245 6 1
 Stage III 220 71 3.1 (1.89, 5.07) 2.21 (1.16, 4.21)*
 Stage IV 24 10 5.93 (2.89, 12.17) 4.05 (1.50, 10.97)**
TB history
 Yes 148 47 1.99 (1.31, 3.05) 0.95 (0.58, 1.55)
 No 341 40 1
CD4 count (cells/μl)
 ≤200 335 260 3.44 (1.83, 6.48) 2.95 (1.48, 5.88)*
 >200 154 142 1
Hemoglobin level (n = 467)
 <10 g/dl 64 18 1.80 (1.06, 3.04) 0.82(0.45, 1.51)
 ≥10 g/dl 403 62 1
Previous OIs
 None 304 15 1
 One 68 18 1.80 (0.99, 3.52) 1.31 (0.69, 2.5)
 2+ 117 54 3.24 (2.05, 5.13) 2.30 (1.11, 4.75)*
HIV related counseling
 Yes 141 6 1
 No 348 81 3.85 (2.44, 6.08) 0.57 (0.26, 1.24)
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Conclusions
Undernutrition at the time of ART initiation was associ-
ated with increased risk of death, particularly during the 
first 3 months after ART initiation. With regard to nutri-
tional status, there was a significant difference in median 
survival time between malnourished adults 35  months 
and non-malnourished adults 52  months. Being mal-
nourished, late WHO stage, having low CD4 cell count, 
ambulatory and bedridden functional status and two and 
more opportunistic infections were factors independently 
associated with death. Interventions to promote earlier 
HIV diagnosis and treatment and nutrition counseling 
should be integrated at all stages of ART implementation, 
such as during adherence counseling, regular follow-up 
sessions, and meetings of PLWHA support groups may 
improve ART outcomes in this vulnerable population.
Abbreviations
AHR: adjusted hazard rate; AIDS: acquired immunodeficiency syndrome; 
ART: antiretroviral therapy; BMI: body mass index; SRS: systematic random 
sampling; CHR: crude hazard rate; CI: confidence interval; Hgb: hemoglobin; 
HIV: human immunodeficiency virus; HR: hazard rate; IQR: inter quartile range; 
Kg: kilogram; OI: opportunistic infection; PLWHA: people living with HIV/AIDS; 
PYO: person-year observation; SD: standard deviation; TB: tuberculosis; WHO: 
World Health Organization.
Authors’ contributions
KT conceived and designed the study, data collection, performed statistical 
analysis and drafted the initial manuscript. NB and KT performed the statistical 
analysis and revised the manuscript. HK performed the statistical analysis and 
initial manuscript draft. All of these authors provided critical comments for 
revision. All authors read and approved the final manuscript.
Author details
1 College of Medicine and Health Sciences, Department of Public Health, 
Ambo University, P.O. Box 21115, Ambo, Ethiopia. 2 School of Public Health, 
Haramaya University, Harar, Ethiopia. 
Acknowledgements
We gratefully acknowledge to all staffs of Fiche hospital, particularly Ejigayehu 
Hailu who helped us during data collection and supervision. We would like 
to thank the School of Public Health of Haramaya University for the financial 
support. Our sincere thanks also goes to Delelegn Yilma and Leul Tadesse 
for their tireless, valuable support and constructive criticism throughout the 
thesis write up.
Competing interests
The authors declare that they have no competing interests.
Ethical approval and consent to publish
Ethical approval was obtained from the Institutional Health Research Ethics 
Review Committee (IHRERC) of Harar campus, Haramaya University, College 
of Medicine and Health Sciences. Following the approval by IHRERC, official 
letter of ethical clearance was written to the concerned bodies by the School 
of Public Health. As the study was conducted through review of medical 
records, the individual patients were not subjected to any harm and personal 
identifiers were not used on data collection forms and confidentiality was 
maintained.
Received: 4 February 2016   Accepted: 1 December 2016
References
 1. World Health Organization. Epidemic update and health sector progress 
towards universal access. Geneva: World Health Organization; 2011.
 2. Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infec-
tion: review of weight loss and wasting in the era of highly active antiret-
roviral therapy from the nutrition for healthy living cohort. Clin Infect Dis. 
2006;42(6):836–42.
 3. World Health Organization. Nutritional care and support for people living 
with HIV/AIDS: a training course. Geneva: World Health Organization; 
2009.
 4. Poda A, Hema A, Zoungrana J, Kaboré NF. Mortality of HIV-infected 
patients on antiretroviral therapy in a large public cohort in West 
Africa, Burkina Faso: frequency and associated factors. Adv Infect Dis. 
2013;3:281–9.
 5. Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP. 
Early mortality in adults initiating antiretroviral therapy (ART) in low- and 
middle-income countries (LMIC): a systematic review and meta-analysis. 
PLoS ONE. 2011;6(12):e28691.
 6. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV 
infected patients taking antiretroviral treatment in Ethiopia: a retrospec-
tive cohort study. AIDS Res Ther. 2012;9(1):15.
 7. Mitiku T, Ali A, Dessie Y. Determinants of mortality among HIV positives 
after initiating antiretroviral therapy in Western Ethiopia: a hospital-based 
retrospective cohort study. ISRN AIDS. 2013. doi:10.1155/2013/491601.
 8. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, 
Makombe S, Harries AD. Risk factors for high early mortality in patients 
on antiretroviral treatment in a rural district of Malawi. AIDS Res Treat. 
2006;20(18):2355–60.
 9. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of 
mortality and non-death losses from an antiretroviral treatment service 
in South Africa: implications for program evaluation. Clin Infect Dis. 
2006;43(6):770–6.
 10. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH. Rapid scale-up 
of antiretroviral therapy at primary care sites in Zambia: feasibility and 
early outcomes. JAMA. 2006;296(7):782–93.
 11. Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, 
Gundersen SG, Bruun JN. Predictors of mortality in HIV-infected patients 
starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect 
Dis. 2008;8:52–60. doi:10.1186/1471-2334-8-52.
 12. Sieleunou I, Souleymanou M, Schonenberger AM, Menten J, Boelaert M. 
Determinants of survival in AIDS patients on antiretroviral therapy in a 
rural centre in the Far-North Province, Cameroon. Trop Med Int Health. 
2009;14(1):36–43.
 13. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among 
adults accessing antiretroviral treatment programmes in sub-Saharan 
Africa. AIDS. 2008;22(15):1897–908.
 14. Koethe JR, Heimburger DC. Nutritional aspects of HIV-associated wasting 
in sub-Saharan Africa. Am J Clin Nutr. 2010;91(4):1138S–42S. doi:10.3945/
ajcn.2010.28608D.
 15. Paton NI, Sangeetha S, Earnest A, Bellamy R. The impact of malnutrition 
on survival and the CD4 count response in HIV infected patients starting 
antiretroviral therapy. HIV Med. 2006;7(5):323–30.
 16. Liu E, Spiegelman D, Semu H. Nutritional status and mortality among 
HIV-infected patients receiving antiretroviral therapy in Tanzania. J Infect 
Dis. 2011;204:282–90.
 17. Hardon AP, Akurut D, Comoro C, et al. Hunger, waiting time and transport 
costs: time to confront challenges to ART adherence in Africa. AIDS Care. 
2007;19(5):658–65.
 18. World Health Organization. Scaling up antiretroviral therapy in resource-
limited settings: treatment guidelines for a public health approach. 
Geneva: World Health Organization; 2003.
 19. Alemu AW, Sebastian MS. Determinants of survival in adult HIV patients 
on antiretroviral therapy in Oromiyaa, Ethiopia. Glob Health Action. 
2010;3:5398. doi:10.3402/gha.v3i0.5398.
 20. Mageda K, Leyna GH, Mmbaga EJ. High initial HIV/AIDS-related mortality 
and-its predictors among patients on antiretroviral therapy in the Kagera 
Region of Tanzania: a five-year retrospective cohort study. AIDS Res Treat. 
2012;2012:843598.
Page 9 of 9Tesfamariam et al. BMC Res Notes  (2016) 9:512 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 21. Bhatta L, Klouman E, Deuba K, Shrestha R. Survival on antiretroviral treat-
ment among adult HIV-infected patients in Nepal: a retrospective cohort 
study in far-western Region, 2006–2011. BMC Infect Dis. 2013;13:604.
 22. Braitstein P, Brinkhof MW, Dabis F, Schechter M. Mortality of HIV-
1-infected patients in the first year of antiretroviral therapy: com-
parison between low-income and high-income countries. Lancet. 
2006;367:817–24.
 23. Tegiste A, Eshetu W. Survival analysis of patients under chronic HIV-care 
and antiretroviral treatment at Tikur Anbessa Specialized Hospital, Addis 
Ababa, Ethiopia. Ethiop J Health Dev. 2012;26(1):22–9.
 24. Jean-François E, Ndiaye I, Thierry-Mieg M, Gueye NF. Mortality and causes 
of death in adults receiving highly active antiretroviral therapy in Senegal: 
a 7-year cohort study. AIDS Care. 2006;20(8):1181–9.
 25. Ketema K, Wencheko E. Survival analysis of HIV-infected patients under 
antiretroviral treatment at the Armed Forces General Teaching Hospital, 
Addis Ababa, Ethiopia. Ethiop J Health Dev. 2012;26(3):186–92.
 26. Abebe N, Alemu K, Asfaw T, Abajobir AA. Predictors of mortality among 
HIV positive adults on antiretroviral therapy in Debremarkos Referral 
Hospital, Northwest Ethiopia. J AIDS HIV Res. 2014;6(1):19–27.
 27. Eyuel T, Alemayehu W. Assessment of antiretroviral treatment outcome 
in public hospitals, South Nations, Nationalities and Peoples Region, 
Ethiopia. Ethiop J Health Dev. 2011;25(2):102–9.
 28. Ghate M, Deshpande S, Tripathy S, Godbole S, Nene M, Thakar M, Risbud 
A, Bollinger R, Mehendale S. Mortality in HIV infected individuals in Pune, 
India. Indian J Med Res. 2011;133(4):414–20.
